Present and future pharmacotherapy for heart failure

Bibliography

• FRANCIS GS: Pathophysiology of chronic heart failure. Am. I Med. (2001) 110(7A):37S–46S.
   Google Scholar
• STEWART S, MACINTYRE K, HOLE DJ, CAPE WELL S, MCMURRAY JJV: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Ear: J. Heart Fail. (2001) 3:315–322.
   PubMed Web of Science ®Google Scholar
• KELLY D: Our future society: a global challenge. Circulation (1997) 95:2459–2464.
   PubMed Web of Science ®Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation (2001) 104:2996–3007.
   PubMed Web of Science ®Google Scholar
• •Recently revised guidelines for the treatment of HE
   Google Scholar
• REMME WJ, SWEDBERG K: Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Ear. J. Heart Fail. (2002) 4:11–22.
   Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe heart failure. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• MOE GW, ROULEAU JL, CHARBONNEAU L et al.: Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am. Heart J. (2000) 139:587–595.
   PubMed Web of Science ®Google Scholar
• CHARRON P, KOMAJDA M: Are we ready for pharmacogenomics in heart failure? Eur. Pharmacol. (2001) 417:1–9.
   Web of Science ®Google Scholar
• YUSUF S, DAGENAIS G, POGUE J, BOSCH J, SLEIGHT P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. I Med. (2000) 342:154–160.
   PubMed Web of Science ®Google Scholar
• REYES AJ: Diuretics in the treatment of patients who present with congestive heart failure and hypertension. f Hum. Hypertens. (2002) 16\(Suppl. 1):5104–5113.
   Google Scholar
• DORMANS TP, GERLAG PG, RUSSEL FG, SMITS P: Combination diuretic therapy in severe congestive heart failure. Drugs (1998) 55:165–172.
   PubMed Web of Science ®Google Scholar
• WONG LL, VERBALIS JG: Vasopressin V2 receptor antagonists. Cardiovasc. Res. (2001) 51:391–402.
   PubMed Web of Science ®Google Scholar
• MARTIN P-Y, ABRAHAM WT, LEMING X et al: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. film. Soc. Nephrol. (1999) 10:2165–2170.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104:2417–2423
   PubMed Web of Science ®Google Scholar
• WHITE M, RACINE N, DUCHARME A, DE CHAMPLAIN J: Therapeutic potential of angiotensin II antagonists. Expert Opin. Investig. Drugs(2001) 10:1687–1701.
   PubMed Web of Science ®Google Scholar
• UNGER T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. (2002) 89 (Suppl.) :3A–10A.
   Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. I Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl. I Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:812–828.
   PubMed Web of Science ®Google Scholar
• THE NETWORK INVESTIGATORS: Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Ear: Heart J. (1998) 19: 481–489.
   PubMed Web of Science ®Google Scholar
• TANG WHW, VAGELOS RH, YEE Y-G et al.: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. I Am. Coll Cardiol. (2002) 39:70–78.
   PubMed Web of Science ®Google Scholar
• PACKER M, POOLE-WILSON PA, ARMSTRONG PW et al.: Comparative effects of low doses and high doses of the angiotensin converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation (1999) 100:2312–2318.
   PubMed Web of Science ®Google Scholar
• •Trial showing the benefit of increasing the dose of ACEI.
   Google Scholar
• RYDEN L, ARMSTRONG PW, CLELAND JG et al.: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Ear: Heart I. (2000) 21:1967–1978.
   PubMed Web of Science ®Google Scholar
• SCULPHER MJ, POOLE L, CLELAND J et al.: Low doses versus high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Eur. I Heart Fail. (2000) 2:447–454.
   PubMed Web of Science ®Google Scholar
• DAVIE AP, DARGIE HJ, MCMURRAY JJ: Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation (1999) 20:268–273.
   Google Scholar
• ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. (1992) 117:234–242.
   PubMed Web of Science ®Google Scholar
• WARNER KK, VISCONTI JA, TSCHAMPEL MM: Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann. Pharmacother. (2000) 34:526–528.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, CHANG P, WILLENHEIMER R et al: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J. Am. Coll Cardiol. (1995) 26:438–445.
   PubMed Web of Science ®Google Scholar
• RIEGGER GA, BOUZO H, PETR P et al.: Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224–2230.
   PubMed Web of Science ®Google Scholar
• PITT B, SE GAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• •Trial showing similar mortality rates with ACEI and ATI antagonist.
   Google Scholar
• HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99:990–992.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANANAD I, COHEN IS et al.: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation (1999) 99:2658–2664.
   PubMed Web of Science ®Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation (1999) 100:1056–1064.
   Google Scholar
• •Trial showing the benefits of ACE inhibition and ATi antagonist combination
   Google Scholar
• GRANGER CB, ERTL G, KUCH J et al.: Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. (2000) 139:609–617.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G, VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M GRANGER C et al: Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J. Card. Fail. (1999) 5:276–282.
   PubMedGoogle Scholar
• YUSUF S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am. J. Cardiol (2002) 89 (Suppl.):18A–26A.
   Google Scholar
• JONG P, DEMERS C, MCKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll Cardiol (2002) 39:463–470.
   PubMed Web of Science ®Google Scholar
• DOGGRELL SA, BROWN L: The spironolactone renaissance. Expert Opin. Investig. Drugs (2001) 10:943–954.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et a/.:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. J. Med. (1999) 10:709–717.
   Google Scholar
• •Landmark trial showing the benefit of spironolactone in severe HE
   Google Scholar
• FARQUHARSON CAJ, STRUTHERS AD: Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 101:594–597.
   PubMed Web of Science ®Google Scholar
• ZANNAD F, ALLA F, DOUSSET B, PEREZ A, PITT B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (PALES). Circulation (2000) 102:2270–2276.
   Web of Science ®Google Scholar
• THE PALES INVESTIGATORS: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]) . Am. Cardiol. (1996) 78:902–907.
   Google Scholar
• •Trial suggesting that spironolactone will benefit mild-to-moderate HE
   Google Scholar
• DELYANI JA, ROCHA R, COOK CS et al.: Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev (2001) 19:185–200.
   PubMed Web of Science ®Google Scholar
• PITT B, WILLIAMS G, REMME W et al:The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. (2001) 15:79–87.
   PubMed Web of Science ®Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl. J. Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• •Landmark trial showing the benefits of carvedilol in HE
   Google Scholar
• THE MERIT-HF INVESTIGATORS: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• •Trial showing the benefits of metoprolol in HE
   Google Scholar
• DOGGRELL SA: Carvedilol versus other P-blockers in heart failure. Expert Opin. Investig. Drugs (2001) 10:971–980.
   PubMed Web of Science ®Google Scholar
• HJALMARSON A, GOLDSTEIN S, FAGERBERG B et al.: Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). "AMA (2000) 283:1295–1302.
   Google Scholar
• GHALI JK, PINA IL, GOTTLIEB SS et al.: Metopolol CR/XL in female patients with heart failure. Analysis of the experience in Metoprolol Extended-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Circulation (2002) 105:1585–1591.
   Google Scholar
• PACKER M, COATS AJ, FOWLER MR et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl. I Med. (2001) 344:1651–1658.
   PubMed Web of Science ®Google Scholar
• •Recent trial demonstrating the benefit of carvedilol in severe HE
   Google Scholar
• GOLDSTEIN S, FAGERBERG B, HJALMARSON A et al.: Metoprolol controlled release/extended release in patients with severe heart failure. I Am. Coll. Cardiol (2001) 38:932–938.
   PubMed Web of Science ®Google Scholar
• •Recent trial demonstrating the benefit of metoprolol in severe HE
   Google Scholar
• METRA M, GIUBBINI R, NORARI S et al.: Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (2000) 102:546–551.
   PubMed Web of Science ®Google Scholar
• KUBO T, AZEVEDO ER, NEWTON GE, PARKER JD, FLORAS JS: Lack of evidence for peripheral alphai-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J. Am. Coll. Cardiol (2001) 38:1463–1468
   PubMed Web of Science ®Google Scholar
• AZEVEDO ER, KUBO T, MAK S et al: Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation (2001) 104:2194–2199.
   PubMed Web of Science ®Google Scholar
• ARUMANAYAGAM M, CHAN S, TONG S, SANDERSON JE: Anti-oxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. Cardiovasc. Pharmacol. (2001) 37:48–54.
   PubMed Web of Science ®Google Scholar
• THE CIBIS INVESTIGATORS AND COMMITTEES: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation (1994) 90:1765–1773.
   PubMed Web of Science ®Google Scholar
• THE CIBIS II INVESTIGATORS: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• LECHAT P, HULOT JS, ESCOLANO S et al.: Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation (2001) 103:1428–1433.
   PubMed Web of Science ®Google Scholar
• LEIZOROVICZ A, LECHAT P, CUCHERAL M, BUGNARD F: Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am. Heart I. (2002) 143:301–307.
   Google Scholar
• ERDMANN E, LECHAT, VERKENNE P, WIEMANN H: Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur. I Heart Fail. (2001) 3:469–479.
   PubMed Web of Science ®Google Scholar
• WITCHITZ S, COHEN-SOLAL A, DARTOIS N, WEISSLINGER N, JUSTE K, DARMON JY: Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. Am. Cardiol. (2000) 85:1467–1471.
   PubMed Web of Science ®Google Scholar
• THE BETA-BLOCKER EVALUATION OF SURVIVAL TRIAL INVESTIGATORS: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl. Med. (2001) 344:1659–1667.
   PubMed Web of Science ®Google Scholar
• MAACK C, CREMERS B, FLESCH M et al.: Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. Pharmacol. (2000) 130:1131–1139.
   Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl. Med. (1997) 336:525–533.
   PubMed Web of Science ®Google Scholar
• THACKRAY S, COLETTA A, JONES Pet al: Clinical trials update: highlights of the scientific sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology, CONTAK-D, CHRISTMAS, OPTIME-CHF. Ear: I Heart Fail. (2001) 3:491–494.
   PubMed Web of Science ®Google Scholar
• O'CONNOR CM, GATTIS WA, URETSKY B et al: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart .f. (1999) 138:78–86.
   PubMed Web of Science ®Google Scholar
• NANAS JN, KONTOYANNIS DA, ALEXOPOULOS GP et al: Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest (2001) 119:1173–1178.
   PubMed Web of Science ®Google Scholar
• CAPOMOLLA S, FEBO 0, OPASICH C et al: Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Ear: Heart Fail. (2001) 3:601–610.
   PubMed Web of Science ®Google Scholar
• WANG X, LI MX, SPYRACOPOULOS L et al: Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033.1 Biol. Chem. (2001) 276:25456–25466.
   PubMed Web of Science ®Google Scholar
• DOGGRELL SA, BROWN L: EMD 57033. Drugs of the Future (2002) 27:14–20.
   Web of Science ®Google Scholar
• FIGGITT DP, GILLIES PS, GOA KL: Levosimendan. Drugs (2001) 61:613–627.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA T, BABA A, SUZUKI M et al.: Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am. Cardiol. (2000) 85:1495–1497.
   PubMed Web of Science ®Google Scholar
• UKKONEN H, SARASTE M, AKKILA J et al.: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin. Pharmacol. Ther. (2000) 68:522–531
   PubMed Web of Science ®Google Scholar
• SLAWSKY MT, COLUCCI WS, GOTTLIEB SS et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 102:2222–2227.
   PubMed Web of Science ®Google Scholar
• NIEMINEN MS, AKKILA J, HASENFUSS G et al: Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive hear failure. Am. Coll Cardiol. (2000) 36:1903–1912.
   PubMed Web of Science ®Google Scholar
• GOMES UC, CLELAND JG: Heart failure update. Eur.j Heart Fail. (1999) 1:301–302
   PubMed Web of Science ®Google Scholar
• DOVAL HC, NUL DR, GRANCELLI HO et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en lsuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344:493–498.
   Google Scholar
• SINGH SN, FLETCHER RD, FISHER SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl. I Med. (1995) 333:77–82.
   Google Scholar
• AMIODARONE TRIALS META-ANALYSIS INVESTIGATORS: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet (1997) 350:1417–1424.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis showing that amiodarone prevents sudden cardiac death.
   Google Scholar
• SIM I, MCDONALD KM, LAVORI PW, NORBUTAS CM, HLATKY MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation (1997) 96:2823–2829.
   PubMed Web of Science ®Google Scholar
• •Another meta-analysis showing that amiodarone prevents sudden cardiac death.
   Google Scholar
• DOGGRELL SA: Amiodarone - waxed andwaned and waxed again. Expert Opin. Pharmacother. (2001) 2(11):1877–1890.
   PubMedGoogle Scholar
• KLEIN H, AURICCHIO A, REEK S, GELLER C: New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am.j Cardiol. (1999) 83:91D–97D.
   Google Scholar
• TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl. I Med. (1999) 341:857–865.
   PubMed Web of Science ®Google Scholar
• BRENDORP B, ELMING H, JUN L et al.: QTe interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation (2001) 103:1422–1427.
   PubMed Web of Science ®Google Scholar
• TOMIYAMA H, WATANABE G, ABE M et al.: Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading. Am. Heart .f. (2001) 141:422–427.
   PubMed Web of Science ®Google Scholar
• FORSSMANN W, MEYER M, FORSSMANN K: The renal urodilatin system: clinical implications. Cardiovasc. Res. (2001) 51:450–462.
   PubMed Web of Science ®Google Scholar
• BARLETTA G, LAZZERI C, VECCHIARINO S et al: Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension (1998) 31:802–808.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA M, YASUE H, MORITA E: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 84:1581–1588.
   PubMed Web of Science ®Google Scholar
• CLARKSON PB, WHEELDON NM, MACFADYEN RJ, PRINGLE SD, MACDONALD TM: Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation (1996) 93:2037–2042.
   PubMed Web of Science ®Google Scholar
• HOBBS RE, MILLER LW, BOTT-SILVERMAN C et al: Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. Cardiol. (1996) 78:896–901.
   PubMed Web of Science ®Google Scholar
• YASUE H, YOSHIMURA M: Natriuretic peptides in the treatment of heart failure. Card. Fail. (1996) 2(4, Suppl.):S277–S285.
   Google Scholar
• MARCUS LS, HART D, PACKER M et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 94:3184–3189.
   Google Scholar
• MILLS RM, LE JEMTEL TH, HORTON DP et al.: Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol (1999) 34:155–162.
   PubMed Web of Science ®Google Scholar
• JENSEN KT, EISKJAER H, CARSTENS J, PEDERSEN EB: Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. ScL (Colch) (1999) 96:5–15.
   PubMed Web of Science ®Google Scholar
• NAKAMURA M, ARAKAWA N, YOSHIDA H et al.: Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135:414–420.
   PubMed Web of Science ®Google Scholar
• COLUCCI WS, ELKAYAM U, HORTON DP et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl. I Med. (2000) 343:246–253.
   PubMed Web of Science ®Google Scholar
• •Recent trial demonstrating the benefits of nesiritide in decongested heart failure.
   Google Scholar
• MCCLEAN DR, IKRAM H, GARLICK AH et al: The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure." Am. Coll. Cardiol (2000) 36:479–486.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failue: IMPRESS randomised trial. Lancet (2000) 356:615–620.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, NUSSBERGER J: Vasopeptidase inhibition and angio-oedema. Lancet (2000) 36:479–486.
   Google Scholar
• THACKRAY S, WITTE K, CLARK AL, CLELAND JGF: Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. EuL J. Heart Fail. (2000) 2:209–212.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, NOLL G, RUSCHITZKA FT, LOSCHER TE: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?" Am. Coll. Cardiol (2001) 37:1493–1505.
   PubMed Web of Science ®Google Scholar
• CODY RJ, HASS GJ, BINKLEY PF et al: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 85:504–509.
   PubMed Web of Science ®Google Scholar
• SOTSCH G, KIOWSKI W, YAN X-W et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 98:2262–2268.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BRADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl. I Med. (2002) 346:896–903.
   PubMed Web of Science ®Google Scholar
• SCHALCHER C, COTTER G, REISIN L et al.: The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patiens with advanced heart failure. Am. Heart" (2001) 142:340–349.
   Google Scholar
• TORRE-AMIONE G, YOUNG JB, DURAND J et al.: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001) 103:973–980.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, DURAND JB, NAGUEH S et al.: A pilot safety trial of prolonged (48 h) infusion of the dual endothelin antagonist tezosentan in patients with advanced heart failure. Chest (2001) 120:460–466.
   PubMed Web of Science ®Google Scholar
• COLETTA PP, CLELAND JGF: Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. Heart Fail (2001) 3:747–750.
   PubMed Web of Science ®Google Scholar
• LOUIS A, CLELAND JG, CRABBE S et al.: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER AND RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur. Heart Fail (2001) 3:381–387.
   Google Scholar
• THACKRAY SD, WITTE KKA, KHAND A et al.: Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur. J. Heart Fail (2001) 3:117–124.
   PubMed Web of Science ®Google Scholar
• GIVERTZ MM, COLUCCI WS, LEJEMTEL TH et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101:2922–2927.
   PubMed Web of Science ®Google Scholar
• ADAMOPOULOS S, PARISSIS JT, KREMASTINOS DT: A glossary of circulating cytokines in chronic heart failure. Eur. J. Heart Fail (2002) 3:517–526.
   Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103:1044–1047.
   PubMed Web of Science ®Google Scholar
• FICHTLSCHERER S, ROSSIG L, BREUER S et al.: Tumor necrosis factor antagonisms with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation (2001) 104:3023–3025.
   PubMed Web of Science ®Google Scholar
• PUGLEY MK: Etanercept. Immunex. Carr: Opin. Investig. Drugs (2001) 2:1725–1731.
   PubMedGoogle Scholar
• FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl. I Med. (1996) 334:809–814.
   PubMed Web of Science ®Google Scholar
• TURNER H, WASS JAH: Growth hormone in the treatment of dilated cardiomyopathy. N Engl. I Med. (1996) 335:672–673.
   PubMedGoogle Scholar
• FRUSTACI A, GENTILONI N, RUSSO MA: Growth hormone in the treatment of dilated cardiomyopathy. N Engl. I Med. (1996) 335:673–674.
   Google Scholar
• GENTH-ZOTZ S, ZOTZ R, GEIL S et al.: Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation (1999) 99:18–21.
   PubMed Web of Science ®Google Scholar
• OSTERZIEL KJ, STROHM 0, SCHULER J et al.: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 351:1233–1237.
   Google Scholar
• ISGAARD J, BERGH CH, CAIDAHL K et al.: A placebo controlled study of growth hormone in patients with congestive heart failure. Eur. Heart! (1998) 19:1704–1711.
   PubMed Web of Science ®Google Scholar
• ANKER SD, VOLTERRANI M, PFLAUM C-D et al: Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. I Am. Coll. Cardiol. (2001) 38:443–452.
   PubMed Web of Science ®Google Scholar
• COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl. J. Med. (1986) 314:1547–1552.
   Google Scholar
• ALLHAT COLLABORATIVE RESEARCH GROUP: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorothalidone: the Antihypertensive and Lipid-lowering Treatment Heart Attack Trial (ALLHAT). JAMA (2000) 283:1967–1975.
   PubMed Web of Science ®Google Scholar
• DE VRIES RJM, VAN VELDHUISEN DJ, DUNSELMAN PHJM: Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second generation dihydropyridines. Am. Heart J. (2000) 139:185–194.
   PubMed Web of Science ®Google Scholar
• ELKAYAM U, JOHNSON JV, SHOTAN A et al: Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circu/aton (1999) 99:2652–2657.
   PubMed Web of Science ®Google Scholar
• HAVRANEK EP, MASOUDI FA, WESTFALL KA, WOLFE P, ORDIN DL: Spectrum of heart failure in older patients: results from the National Heart Failure Project. Am. Heart J. (2002) 143: 412–417.
   PubMed Web of Science ®Google Scholar